The first real-world data (RWD) for Yuhan Corp.’s new lung cancer treatment Leclaza (lazertinib) in the second-line treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC) in Korea has been released. The research team, led by Professor Lim Sun-min at the Oncology Division of Yonsei Ca
Exkivity (mobocertinib), Takeda’s targeted agent for EGFR (epidermal growth factor receptor) Exon 20 insertion mutation non-small cell lung cancer (NSCLC), will likely improve patients’ quality of life, too, an expert predicted.Professor Kim Tae-min of the Hemato-Oncology Department at Seoul Nationa
Merz Aesthetics said it recently held the "Confidence To Be" festival at COEX, Seoul, on May 13.According to the company, the festival was designed to directly communicate the meaning of Merz's global "Confidence To Be" campaign to Korean consumers, offering them the opportunity to experience a vari
Amid the rapid growth of type-2 diabetes drugs, Daewoong Pharmaceutical has set a goal to increase the sale of its SGLT-2 inhibitor, Envlo (enavogliflozin), to 100 billion won ($76 million) within three years.Daewoong is determined to grow the 36th homegrown new drug and SGLT 2 (sodium-glucose cotra
Heart failure patients with an ejection fraction rate of greater than 40 percent can use Entresto (sacubitril/valsartan) regardless of the chronicity of the disease or treatment environment, a recent study has shown.Dr. Robert Mentz of Duke University Medical Center unveiled the result of the PARAGL
Quratis said on Monday that the phase 2a clinical trial results of its novel tuberculosis (TB) vaccine for adults and adolescents, QTP101, showed excellent safety and immunogenicity.The phase 2a trial was conducted on 107 healthy adults with a history of Bacillus Calmette–Guérin (BCG) immunization a
Exports made by the Korean healthcare industry have declined almost 25 percent in the first quarter compared to a year earlier due to the low demand for Covid-19-related treatments and diagnostic devices.According to the Korea Health Industry Development Institute (KHIDI), healthcare exports in the
Spinal muscular atrophy (SMA) patients taking Spinraza (nusinersen) are protesting against the Health Insurance Review and Assessment (HIRA), claiming its review of reimbursement standards is inconsistent.A task force comprised of young SMA patients maintained Wednesday that an increasing number of
HanAll Biopharma announced that the U.S. phase 3 clinical trial (VELOS-3) of HL036 (ingredient: tanfanercept), a promising drug candidate for dry eye disease, did not yield statistically significant results for the primary endpoint.HL036 is a biologic drug jointly developed by HanAll Biopharma and D
In late 2020, ahead of the Organon spinoff, a picket was put up at the MSD Korea office, crying against "tosagupang" – an ancient idiom that means killing a dog after hunting is over.Two and a half years later, the same pickets appeared in the same place.MSD Korea’s labor union held a picket on the
Korea has already cemented its position as a leader in Asia with its fast-growing microbiome therapeutics focused on live biotherapeutic products (LBPs). However, domestic microbiome producers are striving to go a step further to develop first-in-class microbiome drugs in niche areas such as autism
Samjin Pharmaceutical said it has signed a joint research agreement with Daehwa Pharmaceutical to develop new antithrombotic drugs.Under the accord, Samjin will discover and optimize candidates for targets selected by Daehwa based on its artificial intelligence drug development capabilities of its i
Tagrisso (osimertinib), AstraZeneca’s third-generation EGFR (estimated glomerular filtration rate) tyrosine kinase inhibitor (TKI), has opened a new way for customized treatment of locally progressive or metastatic non-small cell lung cancer (NSCLC).AZ has recently confirmed Tagrisso’s progression-f
The Financial Services Commission (FSC) has implemented administrative measures against Hyundai Pharmaceutical and Mediforum for violating accounting standards.The Securities and Futures Commission (SFC), which is part of the FSC, held its 10th meeting on Wednesday and voted to sanction Hyundai Phar
Neurophet said on Thursday that it obtained FDA 510k clearance for its AI-based degenerative brain disease diagnosis assistant software, Neurophet AQUA.Neurophet AQUA uses AI algorithms to analyze brain atrophy observed in neurodegenerative diseases such as Alzheimer's disease. It can segment and an
Fecal microbiome transplants (FMT) offer a clinical cure for antibiotic-resistant therapies. However, the industry is focused on developing cultured microbiome strains, said a regulatory expert from Australia.BiomeBank Head of Regulatory Affairs, Mirjana Rapaic, presented on her company’s journey to
HLB said it has filed a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) for combination therapy of rivoceranib and camrelizumab as the first-line treatment for hepatocellular carcinoma (HCC).HLB holds the global patent for rivoceranib.Through its U.S. subsidiary Elevar Th
Daewoong Pharmaceutical’s intestine purifier has entered phase 3 clinical trial, creating a stir in the industry.According to the Ministry of Food and Drug Safety, DWJ1609, Daewoong’s formulation to evacuate bowels won its approval for a phase 3 clinical trial on Tuesday.Daewoong plans to confirm th
“There was this child who always stayed at home because he had to rush to the emergency room frequently, although he received intravenous hemophilia injections every two or three days. Now the child attends kindergarten, as he rarely goes to the hospital after receiving the Hemlibra injection. When
“Mixing cultures is the holy grail, but bacteria don't like collaborating, and achieving repeatability remains the main issue. However, we are experimenting vigorously in this area.”Sacco System’s Global Business Development Director Max Rossetto said so during the Microbiome Asia Conference at Hote